drugset / Trial / NCT03200704

A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

NCT03200704 ↗

Phase 3 Completed 152 enrolled Novadaq Technologies ULC
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 (Indocyanine Green (ICG) for Injection) and the SPY Portable Handheld Imaging System (SPY-PHI) as an intraoperative fluorescence visualization tool, in the visual identification of lymphatic vessels and lymph nodes (LNs) during lymphatic mapping and sentinel lymph node biopsy (SLNB) procedures as confirmed by Technitium99m (Tc99m) and Gamma Probe.

Timeline

Start
2019-01-04
Primary completion
2020-08-27
Completion
2020-09-28

Outcome

Met primary endpoint

registry analysis (non-inferiority test); IC2000/SPY-PHI; p <0.0001; Regression, Logistic NCT03200704 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject IC2000 Diagnostic / imaging agent 0.05 ml Intravenous
Subject IC2000 Diagnostic / imaging agent 2.5 mg/ml Intravenous
Background Tc-99m radioactive colloid Diagnostic / imaging agent — —

Indications